Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free BFRIW Stock Alerts

Biofrontera (BFRIW) Competitors

Biofrontera logo
$0.03 0.00 (0.00%)
As of 07/15/2026
Compare

BFRIW vs. AIMDW, ALVOW, ARAV, ACABW, and CELUW

Should you buy Biofrontera stock or one of its competitors? MarketBeat compares Biofrontera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biofrontera include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry.

How does Biofrontera compare to Ainos?

Ainos (NASDAQ:AIMDW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Ainos and Ainos both had 1 articles in the media. Biofrontera's average media sentiment score of 1.87 beat Ainos' score of 1.74 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Ainos Very Positive
Biofrontera Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Summary

Biofrontera beats Ainos on 2 of the 2 factors compared between the two stocks.

How does Biofrontera compare to Alvotech?

Biofrontera (NASDAQ:BFRIW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Alvotech's average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Very Positive
Alvotech Very Positive

Summary

Alvotech beats Biofrontera on 2 of the 2 factors compared between the two stocks.

How does Biofrontera compare to Aravive?

Biofrontera (NASDAQ:BFRIW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Biofrontera had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Aravive. Biofrontera's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Biofrontera beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Biofrontera compare to Atlantic Coastal Acquisition Corp. II?

Biofrontera (NASDAQ:BFRIW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

In the previous week, Biofrontera had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Atlantic Coastal Acquisition Corp. II. Biofrontera's average media sentiment score of 1.87 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Atlantic Coastal Acquisition Corp. II Neutral

Summary

Biofrontera beats Atlantic Coastal Acquisition Corp. II on 3 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Celularity?

Celularity (NASDAQ:CELUW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Celularity and Celularity both had 1 articles in the media. Celularity's average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that Celularity is being referred to more favorably in the media.

Company Overall Sentiment
Celularity Very Positive
Biofrontera Very Positive

Company Net Margins Return on Equity Return on Assets
CelularityN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celularity$26.55MN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Summary

Celularity and Biofrontera tied by winning 1 of the 2 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Sign up to receive the latest news and ratings for BFRIW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRIW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFRIW vs. The Competition

Export
MetricBiofronteraDrug Manufacturers IndustryMedical SectorNASDAQ Exchange
Market CapN/A$5.83B$6.96B$12.67B
Dividend YieldN/A2.82%2.68%8.87%
P/E RatioN/A5.0527.2024.05
Price / SalesN/A1,652.92578.13112.08
Price / CashN/A10.1849.2559.89
Price / BookN/A10.6110.746.23
Net IncomeN/A$20.27B$3.59B$331.94M
7 Day PerformanceN/A-0.15%-1.92%-1.65%
1 Month PerformanceN/A-0.31%2.23%-1.03%
1 Year PerformanceN/A7.89%23.82%17.10%

Biofrontera Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BFRIW
Biofrontera
N/A$0.03
flat		N/A-70.6%$0.00$43.20MN/A70
AIMDW
Ainos
N/A$0.15
-3.3%		N/A-47.1%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.13
flat		N/A-90.3%$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BFRIW) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel